Method of predicting a response to an anti-tumor treatment

1. A method for treating a tumor in a patient, which method comprises

a) determining expression level of at least each of VIM, MK167, TCF7L2, NEK2, BIRC5, MCL1, and PLK1 genes, in a biological sample of a patient with a tumor, wherein a decreased expression of said genes compared to control values for said genes is indicative of a patient being likely to respond to a treatment with a chimeric peptide comprising i) a pro-apoptotic peptide that comprises SEQ ID NO: 4 or SEQ ID NO: 1 fused at the C-terminus to ii) a cell-penetrating peptide that comprises a sequence selected from the group consisting of SEQ ID NO: 26, 27, 28 and 29; and

b) administering said chimeric peptide to a patient having decreased expression of at least each of VIM, MK167, TCF7L2, NEK2, BIRC5, MCL1, and PLK1 genes compared to control values for said genes.

2. The method of claim 1 , wherein the pro-apoptotic peptide is SEQ ID NO: 4 and the cell-penetrating peptide is SEQ ID NO: 26 or SEQ ID NO: 27.

3. The method of claim 1 , wherein the tumor is a cancer selected from the group consisting of a breast tumor, an ovarian tumor, a lung tumor, a colon tumor and a prostate tumor, or is a tumor selected from the group consisting of acute myelogenous leukaemia, chronic lymphocytic leukaemia, multiple myeloma, Hodgkin's disease, non-Hodgkin's lymphoma, B cell, cutaneous T cell lymphoma, brain, head and neck, bladder, gastric, pancreatic, head, neck, renal, prostate, colorectal, oesophageal, thyroid cancer, uveal melanoma and melanoma.

4. The method of claim 1 , wherein the expression levels of said genes is determined by RT-PCR amplification.